Squarex Pharma

Squarex Pharma is a clinical-stage pharmaceutical company developing a novel topical immunotherapy for the prevention of recurrent herpes labialis (cold sores) and other viral-related dermatological conditions. The company's lead candidate, SQX770, is a topical formulation of squaric acid dibutyl ester (SADBE) designed to stimulate the patient's immune system to prevent outbreaks. By inducing a delayed-type hypersensitivity reaction, the treatment aims to enhance the T-cell mediated immune response against the latent virus. Squarex has successfully completed Phase 2 clinical trials demonstrating a significant reduction in the frequency of cold sore outbreaks. The company is also exploring the application of its immunotherapeutic approach for indications such as alopecia areata and common warts.